First Advisor

Samantha Underwood

Date of Award

Summer 8-2022

Document Type


Degree Name

Bachelor of Science (B.S.) in Biology and University Honors






Thrombophlebitis -- Prevention, Drugs -- Dosage, Overweight persons -- Wounds and injuries




Deep vein thrombosis (DVT) is a frequent occurrence in trauma patients secondary to traumatic injury due to immobilization, reparative surgeries, and procedures, if no/minimal prophylaxis is utilized. Obesity has been shown to increase the risk of venous thromboembolism (VTE) by 2 to 3 times. The current DVT data may not discriminate between patient demographics that affect venous thromboembolisms (VTE) and chemoprophylaxis, such as weight or body mass index (BMI). A retrospective data analysis was performed using data collected from Oregon Health & Science University’s Trauma Registry that includes trauma patients admitted between January 2017 and December 2020, ≥17 years of age, ≥30 kg/m2, who had an Injury Severity Score (ISS) of ≥9, and who received the FDA-approved medication enoxaparin to prevent the occurrence of DVTs. A significant difference was found between the group of patients who received 60 mg of enoxaparin and the 30 BID group, the 40 mg QD group, and the group containing all other dosing schedules (80, 90, 100, 105, 120, or 135 mg) (p < 0.01). Our hypothesis is that higher body weight and BMI will correlate with larger enoxaparin doses, and therefore a non-standard dosing strategy will lower DVT rates in this population.


In Copyright. URI: This Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).

Persistent Identifier